More on MRD... Dr. W. Wierda, MDAnderson - CLL Support
More on MRD... Dr. W. Wierda, MDAnderson
You need to be a member of this community to see this post.
Read more about...
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
Measurable residual disease (MRD) status predicts Progression Free Survival (PFS) for patients with Chronic Lymphocytic Leukemia (CLL)
Measurable residual disease (MRD) refers to the presence of disease at low levels not detected...
Use of MRD Status Following Obinutuzumab/Ibrutinib to Guide Subsequent Intensification of Therapy in CLL
August 6, 2019
In this 2-part, single-arm, open-label, multicenter trial (Clinical Trials.gov...
Dr. John Allan - Chronic Lymphocytic Leukemia (CLL) Patients @Undetectable Measurable Residual Disease (MRD) after Ibrutinib Plus Venetoclax
ASH 2022: Dr. John Allan on Outcomes for Chronic Lymphocytic Leukemia (CLL) Patients with...
Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: Update on The CLARITY Study
Published on line July 11, 2019, Accepted by JCO May 31 2019
Dr P Hillmen
We have some members who...
Dr. Shadman on Fixed Durations of Treatment in CLL
Mazyar Shadman, MD, MPH
Published: Monday, Jul 08, 2019
Mazyar Shadman, MD, MPH, assistant member,...
Related Posts
“MRD: What Should It Mean to Me?” Ever dreamed of coming to a point where your CLL treatment could be safely stopped? View CLL Webinar.- Can Venetoclax/Obinituzimab reduce the risk of additional somatic mutations? - Not necessarily. The BTK inhibitors are excellent at....
- Acalabrutinib Plus Venetoclax and Obinutuzumab Achieves High Bone Marrow uMRD Rate in Chronic Lymphocytic Leukemia - CLL
Response and Survival Rates for FCR and Ibrutinib- Dr. Wierda on the Importance of Clinical Trials
